TECH

Bio-Techne Corporation TECH reported adjusted earnings per share of 52 cents for the fourth quarter of fiscal 2026, which dropped 1.9% year over year and came in line with the Zacks Consensus Estimate. The quarter's adjustments eliminated the impact of certain items, including amortization of intangibles and Wilson Wolf intangible assets, acquisition-related expenses, certain litigation charges, stock-based compensation, restructuring and restructuring-related costs, and investment-related losses, among others. GAAP EPS was 35 cents compared to a loss of 11 cents in the prior-year quarter. For the full year, adjusted EPS of $1.93 increased 0.5% from the fiscal 2025 adjusted figure and surpassed the consensus mark by 1%. In the fiscal fourth quarter, net sales came in at $321.2 million, up 1% year over year on a reported basis and 3% on an organic basis. The figure surpassed the Zacks Consensus Estimate by 1.26%. Full-year revenues were $1.22 billion, remaining flat from fiscal 2025 on both a reported and organic basis. Foreign currency had a favorable impact of 2%, while a business held for sale had an unfavorable impact of 2%. The metric came 0.8% above the consensus mark. Following the announcement, TECH shares edged up 0.1% to close yesterday’s session at $72.23. Within Protein Sciences, Bio-Techne recorded revenues of $231.2 million, up 2% year over year from $226.5 million. Organic revenues increased 1%, while foreign currency had a favorable impact of 1%. Bio-Techne Corp price-consensus-eps-surprise-chart | Bio-Techne Corp Quote Within Diagnostics and Spatial Biology, revenues were $90.1 million, roughly flat from $89.7 million in the prior-year quarter. Organic revenues increased 8%, while the held-for-sale business had an unfavorable impact of 8%. Bio-Techne’s gross profit increased 6.3% year over year to $211.4 million. The gross margin expanded 310 basis points (bps) to 65.8% as the cost of sales declined 7.1% to $109.8 million. Adjusted gross margin, however, contracted 80 basis points (bps) to 69.2%. Selling, general and administrative expenses declined 42.4% to $113.2 million. Research and development expenses totaled $23.9 million, down 8.0% year over year. Total operating expenses fell 38.4% to $137.1 million from $222.7 million in the prior-year quarter. The company generated operating income of $74.3 million in the fiscal fourth quarter compared to an operating loss of $23.9 million in the year-ago quarter. Bio-Techne exited fiscal 2026 with cash and equivalents of $264.7 million compared with $162.2 million at the end of fiscal 2025. Long-term debt obligations totaled $200 million compared with $346 million at the end of the prior fiscal year. Cumulative net cash provided by operating activities was $292.1 million at the end of fiscal 2026 compared with $287.6 million a year ago. On June 25, 2026, Bio-Techne entered into an agreement to be acquired by Merck KGaA, Darmstadt, Germany, for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion. Management said it continues to make progress toward completing the transaction and expects the combination to create opportunities for the company’s customers and employees. In light of the announced deal, Bio-Techne is no longer holding investor conference calls for quarterly results. Bio-Techne exited the fourth quarter of fiscal 2026 with in-line earnings, while revenues surpassed estimates. Protein Sciences posted modest growth, supported by underlying organic gains, though unfavorable volume and product mix pressured segment profitability. Diagnostics and Spatial Biology delivered stronger organic growth and improved profitability, helped by favorable volume trends, ongoing profitability initiatives and the Exosome Diagnostics divestiture. Meanwhile, the contraction in adjusted gross margin during the quarter is discouraging. Bio-Techne currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks from the broader medical space are Labcorp Holdings LH, Quest Diagnostics DGX and Medpace MEDP. Labcorp, carrying a Zacks Rank #2 (Buy), reported second-quarter 2026 adjusted EPS of $4.99, which surpassed the Zacks Consensus Estimate by 4.18%. Revenues of $3.73 billion beat the Zacks Consensus Estimate by 0.36%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. LH has an earnings yield of 5.9% compared with the industry’s 4.1% yield. The company's earnings beat estimates in each of the trailing four quarters, the average surprise being 3.09%. Quest Diagnostics, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $3.12, exceeding the Zacks Consensus Estimate by 11%. Revenues of $3.04 billion topped the Zacks Consensus Estimate by 2.1%. DGX has an earnings yield of 4.7%, almost in line with the industry’s yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 5.77%. Medpace, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $4.25, exceeding the Zacks Consensus Estimate by 4.17%. Revenues of $707.3 million outperformed the consensus mark by 1.12%. MEDP has a historical five-year earnings growth rate of 30.5% compared with the industry’s 5.6% growth. In the trailing four quarters, the company delivered an average earnings beat of 10.16%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Labcorp Holdings Inc. (LH) : Free Stock Analysis Report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report Bio-Techne Corp (TECH) : Free Stock Analysis Report Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

MINNEAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2026. Fourth Quarter FY2026 Highlights Fourth quarter organic revenue increased by 3% (1% reported) to $321.2 million. Full year organic and reported revenue remained flat at $1.2 billion. GAAP EPS increased to $0.35 from $(0.11) one year ago. Delivered adjusted EPS was $0.52, down from $0.53 one year ago. Full year GAAP EPS increased to $1.16 versus $0.46 one year ago. Full year adjusted EPS was $1.93, up from $1.92 one year ago. As previously announced on June 25, 2026, Bio-Techne entered into an agreement to be acquired by Merck KGaA, Darmstadt, Germany for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion. "Bio-Techne ended fiscal 2026 with improved performance and solid execution across the business, reflecting the value our differentiated solutions bring across biopharma, research and diagnostic workflows," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "We continue to make progress toward completing Bio-Techne's acquisition by Merck KGaA, Darmstadt, Germany, and look forward to the opportunities this transaction is expected to create for our customers and employees." Conference Call In light of the announced transaction with Merck KGaA, Darmstadt, Germany, Bio-Techne is no longer holding investor conference calls for quarterly results. Fourth Quarter Fiscal 2026 Revenue Net sales for the fourth quarter increased 1% to $321.2 million. Organic growth increased 3% compared to the prior year. Non-recurring prior year revenue from a business held-for-sale had an unfavorable impact of 2% and foreign currency exchange did not have a material impact. GAAP Earnings Results GAAP EPS was $0.35 per diluted share versus $(0.11) in the same quarter last year. GAAP operating income for the fourth quarter of fiscal 2026 was $74.3 million compared to an operating loss of $23.9 million in the fourth quarter of fiscal 2025. GAAP operating margin was 23.1% compared to (7.5)% in the fourth quarter of fiscal 2025. Current quarter GAAP operating margin was favorably impacted by a non-recurring impairment charge in the prior year. Non-GAAP Earnings Results Adjusted EPS decreased to $0.52 per diluted share compared to $0.53 in the same quarter last year. Adjusted operating income increased to $103.4 million in the fourth quarter of fiscal 2026 compared to $101.3 million in the fourth quarter of fiscal 2025. Adjusted operating margin was 32.2% for the fourth quarter of fiscal 2026 compared to 32.0% in the fourth quarter of fiscal 2025. Adjusted operating margin was favorably impacted by profitability initiatives and the Exosome Diagnostics divestiture, partially offset by unfavorable product mix. Full Year Fiscal 2026 Revenue Net sales for the full year fiscal 2026 remained flat from the prior year at $1.2 billion. Organic revenue remained flat from the prior year. Foreign currency exchange had a favorable impact of 2% and a business held-for-sale had an unfavorable impact of 2%. GAAP Earnings Results GAAP EPS was $1.16 per diluted share, compared to $0.46 last fiscal year. GAAP operating income for full year fiscal 2026 increased 146% to $251.9 million, compared to $102.3 million in the full year fiscal 2025. GAAP operating margin was 20.7% compared to 8.4% in the full year fiscal 2025. GAAP operating margin was favorably impacted by a non-recurring impairment charge in the prior year, a non-recurring arbitration award in the prior year, and a recovery of assets held-for-sale. Non-GAAP Earnings Results Adjusted EPS increased to $1.93 per diluted share, compared to $1.92 last fiscal year. Adjusted operating income for fiscal 2026 increased 1% to $386.1 million, compared to $383.6 million for fiscal 2025. Adjusted operating margin was favorably impacted by profitability initiatives and the Exosome Diagnostics divestiture. Segment Results Management uses adjusted operating results to monitor and evaluate performance of the Company's business segments, as highlighted below. Protein Sciences Segment The Company's Protein Sciences segment is one of the world's leading suppliers of specialized proteins such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biopharma and academic research communities. Additionally, the segment provides an array of platforms essential in various areas of protein analysis. The Protein Sciences segment's fourth quarter fiscal 2026 net sales were $231.2 million, an increase of 2% from $226.5 million in the fourth quarter of fiscal 2025. As of December 31, 2023, a business within the Protein Sciences segment met the criteria as held-for-sale; this held-for-sale business has been excluded from the segment's operating results for both periods presented. Organic revenue increased 1% for the fourth quarter of fiscal 2026, with foreign currency exchange having a favorable impact of 1%. The Protein Sciences segment's operating margin decreased to 42.0% in the fourth quarter of fiscal 2026 compared to 43.6% in the fourth quarter of fiscal 2025. The segment's operating margin decreased primarily due to unfavorable volume and product mix. Protein Sciences segment's full year fiscal 2026 net sales were $874.6 million, an increase of 1% from $870.2 million for full year fiscal 2025. Organic revenue for the segment decreased 1% for the fiscal year, with foreign currency exchange having a favorable impact of 2%. Protein Sciences segment's operating margin was 41.1% in fiscal 2026 compared to 42.6% in fiscal 2025. The segment's operating margin was impacted by unfavorable volume and product mix. Diagnostics and Spatial Biology Segment The Company's Diagnostics and Spatial Biology segment develops and provides spatial biology products, carrier screening and oncology kits. The Diagnostics and Spatial Biology segment also provides blood chemistry and blood gas quality controls, hematology instrument controls, immunoassays and other bulk and custom reagents for the in vitro diagnostic market. The Diagnostics and Spatial Biology segment's fourth quarter fiscal 2026 net sales remained flat at $90.1 million, as compared to $89.7 million in the fourth quarter of fiscal 2025. As of June 30, 2025, a business within the Diagnostics and Spatial Biology segment met the criteria as held-for-sale; this held-for-sale business has been excluded from the segment's fiscal 2026 operating results. Organic revenue increased 8% for the fourth quarter of fiscal 2026, with foreign exchange not having a material impact. The held-for-sale business had an unfavorable impact of 8%. The Diagnostics and Spatial Biology segment's operating margin increased to 11.2% in the fourth quarter of fiscal 2026 compared to 6.0% in the fourth quarter of fiscal 2025. The segment's operating margin was favorably impacted by the Exosome Diagnostics divestiture, favorable volume growth, and ongoing profitability initiatives. The Diagnostics and Spatial Biology segment's full year fiscal 2026 net sales were $336.4 million, a decrease of 3% from $346.3 million for the full year fiscal 2025. Organic growth for the segment was 4%, with foreign currency exchange having a favorable impact of 1%. A business held-for-sale had an unfavorable impact of 8%. The Diagnostics and Spatial Biology segment's operating margin was 11.2% in fiscal 2026 compared to 6.2% in fiscal 2025. The segment's operating margin was impacted by the divestiture of Exosome Diagnostics, favorable volume growth, and ongoing profitability initiatives. About Bio-Techne Bio‑Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high‑quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer‑focused brands: R&D Systems™, Bio‑Techne Spatial™, and Bio‑Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision‑making. Bio‑Techne operates in 34 locations worldwide and employs approximately 3,000 people. In fiscal year 2026, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories. For more information on Bio-Techne and its brands, please visit www.bio-techne.com or follow the company on social media at LinkedIn, X, or YouTube. Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These statements use words and variations of words, such as "will," "plan," "continue," "believe," "outlook," "expect," and "predict." These statements are made as of the date of this press release, are based on current expectations of future events, and thus are inherently subject to a number of risks and uncertainties, many of which involve factors or circumstances beyond the Company's control. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. These risks, uncertainties, and other factors include, without limitation: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships. For additional information concerning these risks, uncertainties, and other factors, see the section titled "Risk Factors" in the Company's most recent annual report on Form 10-K as filed with the Securities and Exchange Commission. We undertake and we expressly disclaim any obligation to update or revise any forward-looking statements due to new information, changed assumptions, or future events, except as required by law. Investors are cautioned not to place undue reliance on forward-looking statements. Non-GAAP Financial Measures: The Company's financial statements are prepared in accordance with accounting principles generally accepted in the U.S. (GAAP). This press release contains financial measures that have not been calculated in accordance with GAAP. These non-GAAP measures include: Organic revenue and organic revenue growth Adjusted gross margin Earnings before interest, taxes, depreciation, and amortization (EBITDA) Adjusted EBITDA Adjusted operating income Adjusted operating margin Adjusted tax rate Adjusted net earnings Adjusted diluted earnings per share These non-GAAP measures should not be considered in isolation or as a substitute for any measure derived in accordance with GAAP and may also be inconsistent with similar measures presented by other companies. Reconciliations of these measures to the applicable most closely comparable GAAP measures, and reasons for the Company's use of these measures, are presented in the attached pages. Use of Non-GAAP Financial Measures: This press release contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results. Investors are encouraged to review the reconciliations of non-GAAP financial measures used in this press release to their most directly comparable GAAP financial measures as provided with the financial statements attached to this press release. Our non-GAAP financial measure of organic revenue and organic revenue growth represent revenue growth excluding revenue from acquisitions within the preceding 12 months, the impact of foreign currency, as well as the impact of businesses held-for-sale. Excluding these measures provides more useful period-to-period comparison of revenue results as it excludes the impact of foreign currency exchange rates, which can vary significantly from period to period, and revenue from acquisitions that would not be included in the comparable prior period. Revenues from businesses held-for-sale are excluded from our organic revenue calculation starting on the date they become held-for-sale as those revenues will not be comparative in future periods. Our non-GAAP financial measures for adjusted gross margin, adjusted operating margin, adjusted EBITDA, and adjusted net earnings, in total and on a per share basis, exclude stock-based compensation, which is inclusive of the employer portion of payroll taxes on those stock awards, the costs recognized upon the sale of acquired inventory, amortization of acquisition intangibles, and restructuring and restructuring-related costs. Stock-based compensation is excluded from non-GAAP adjusted net earnings because of the nature of this charge, specifically the varying available valuation methodologies, subjective assumptions, variety of award types, and unpredictability of amount and timing of employer related tax obligations. The Company excludes amortization of purchased intangible assets, purchase accounting adjustments, including costs recognized upon the sale of acquired inventory, and other non-recurring items including gains or losses on goodwill and long-lived asset impairment charges, and one-time assessments from this measure because they occur as a result of specific events, and are not reflective of our internal investments, the costs of developing, producing, supporting and selling our products, and the other ongoing costs to support our operating structure. Costs related to restructuring and restructuring-related activities, including reducing overhead and consolidating facilities, are excluded because we believe they are not indicative of our normal operating costs. Additionally, these amounts can vary significantly from period to period based on current activity. The Company also excludes revenue and expense attributable to businesses held-for-sale in the calculation of our non-GAAP financial measures. The Company's non-GAAP adjusted operating margin, adjusted EBITDA, and adjusted net earnings, in total and on a per share basis, also excludes acquisition related expenses inclusive of the changes in fair value of contingent consideration, and other non-recurring items including certain costs related to goodwill and long-lived asset impairments, and gains. We also exclude certain litigation charges which are facts and circumstances specific including costs to resolve litigation and legal settlement (gains and losses). In some cases, these costs may be a result of litigation matters at acquired companies that were not probable, inestimable, or unresolved at the time of acquisition. The Company's non-GAAP adjusted EBITDA and adjusted net earnings, in total and on a per share basis, also excludes gains and losses from investments, as they are not part of our day-to-day operating decisions (excluding our equity method investment in Wilson Wolf as it is certain to be acquired in the future) and certain adjustments to income tax expense. Additionally, gains and losses from investments that are either isolated or cannot be expected to occur again with any predictability are excluded. The Company independently calculates a non-GAAP adjusted tax rate to be applied to the identified non-GAAP adjustments considering the impact of discrete items on these adjustments and the jurisdictional mix of the adjustments. In addition, the tax impact of other discrete and non-recurring charges which impact our reported GAAP tax rate are adjusted from net earnings. We believe these tax items can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results. View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-releases-fourth-quarter-fiscal-2026-results-302849060.html

Bio-Techne Corporation TECH is expected to release fourth-quarter fiscal 2026 results on Aug. 5. The life science and diagnostic product maker posted adjusted earnings per share (EPS) of 53 cents in the last reported quarter, missing the Zacks Consensus Estimate by 3.64%. The company’s earnings beat estimates in two of the trailing four quarters, matched once and missed in the other, the average surprise being 2.34%. The Zacks Consensus Estimate for revenues is pegged at $317.2 million, indicating an increase of 0.1% from the year-ago reported figure. The consensus estimate for EPS is pinned at 52 cents, implying a decrease of 1.9% from the year-ago reported figure. Estimates for earnings have remained constant at 52 cents per share in the past 30 days. Let’s briefly review the company’s performance leading up to the announcement. In June 2026, Merck KGaA, Darmstadt, Germany, a leading science and technology company, entered into a definitive agreement to acquire Bio-Techne for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion. The proposed transaction has been approved by Bio-Techne's board of directors and the relevant corporate bodies of Merck KGaA, Darmstadt, Germany, and is expected to be closed by late 2026 or early 2027, subject to satisfaction of customary closing conditions. Protein Sciences The company’s core portfolio of research-use-only proteomic agents, featuring more than 6,000 proteins and 400,000 antibody types, declined at a mid-single-digit rate in the previous quarter. However, as the normalization of funding conditions in academia and recent improvements in biotech funding translated into customer spending, this core portfolio might have returned to growth in the to-be-reported quarter. Aside from the two largest cell therapy customers (who temporarily reduced purchases), GMP reagents are likely to have witnessed strong growth, underscoring the strength of its offering and improving end-market demand. In the fiscal fourth quarter, the protein analytical instrumentation business might have continued to demonstrate strong momentum, driven by the Ella benchtop immunoassay platform. Bio-Techne is also expected to have experienced continued traction across the biologic characterization portfolio led by the Maurice platform during the to-be-reported quarter. The Wilson Wolf business must have stood out as a high-growth opportunity despite the challenging biotech funding environment. In the previous quarter, the company launched Simple Plex Ultra-Sensitive Assays on the Ella automated benchtop platform and Cultrex Synthetic Hydrogel to support reproducible and scalable 3D stem cell and organoid research. Additionally, the Ella benchtop immunoassay platform has received CE-IVD marking and is now available for sale in the European Union. These initiatives might have contributed to the company’s fiscal fourth-quarter top-line performance. The consensus estimate for the segment’s revenues is pegged at $227.2 million, down 0.3% from the year-ago reported figure. Bio-Techne Corp price-eps-surprise | Bio-Techne Corp Quote Diagnostics and Spatial In the fiscal fourth quarter, the RNAscope product suite, which is used to detect and visualize RNA and short microRNA sequences at the single-cell level within intact tissue samples, might have experienced growth similar to that reported in the previous quarter. The growth was likely driven by continued customer adoption across the EMEA and Asia-Pacific regions, as well as increasing use of the technology in clinical diagnostic applications in the United States. The COMET Multiomic Spatial platform might have recorded year-over-year growth in bookings. In the previous quarter, the Diagnostics business saw sales decline as order timing from certain large customers temporarily impacted the results. Management noted that the business remains susceptible to quarter-to-quarter volatility due to its concentration of large customers. This dynamic could have weighed on top-line growth in the to-be-reported quarter. Notable development within the segment includes the expansion of its COMET solution portfolio in China, an important milestone as demand continues to build in the region. The consensus estimate for Diagnostics and Spatial revenues is pegged at $88.3 million, down 1.6% from the year-ago reported figure. Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see. Earnings ESP: Bio-Techne has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. Zacks Rank: The company currently carries a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank stocks here. Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around: Hinge Health Inc. HNGE has an Earnings ESP of +4.24% and a Zacks Rank #1 at present. The company is expected to release second-quarter 2026 results soon. In the trailing four quarters, HINGE delivered an average earnings surprise of 179.54%. The Zacks Consensus Estimate for second-quarter EPS implies a decrease of 11.9% from the year-ago reported figure. Neurocrine Biosciences NBIX has an Earnings ESP of +40.60% and a Zacks Rank #1 at present. The company is expected to release second-quarter 2026 results soon. NBIX’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 9.08%. The Zacks Consensus Estimate for the company’s second-quarter EPS calls for an increase of 112.3% from the year-ago quarter’s figure. West Pharmaceutical Services WST has an Earnings ESP of +1.09% and a Zacks Rank #2 at present. The company is slated to release second-quarter 2026 results on July 23. WST’s earnings beat estimates in each of the trailing four quarters, the average surprise being 19.37%. The Zacks Consensus Estimate for WST’s second-quarter EPS implies a rise of 13% from the year-ago reported figure. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bio-Techne Corp (TECH) : Free Stock Analysis Report Neurocrine Biosciences, Inc. (NBIX) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report Hinge Health Inc. (HNGE) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

With a market cap of $11.3 billion, Bio-Techne Corporation (TECH) is a global life sciences company that develops, manufactures, and sells reagents, instruments, and services for research, diagnostics, and bioprocessing applications. It operates through its Protein Sciences and Diagnostics and Spatial Biology segments, providing innovative solutions for life science research, cell and gene therapy, molecular diagnostics, and spatial biology. The Minneapolis, Minnesota-based company is slated to announce its fiscal Q4 2026 results soon. Ahead of the event, analysts expect TECH to report an EPS of $0.46, down 9.8% from $0.51 in the year-ago quarter. However, it has surpassed or met Wall Street's bottom-line estimates in each of the past four quarterly reports. Alibaba Stock Just Got Apple’s Biggest AI Endorsement. This Could Be a Game Changer for BABA. Elon Musk Says If SpaceX Accomplishes Its Goals, ‘It Will Be Worth More Than The Rest of Earth’ — Though He’s Also Said ‘Money Will Stop Being Relevant’ AI Bubble Fears, Earnings and Other Can't Miss Items this Week Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! For fiscal 2026, analysts predict Bio-Techne to post EPS of $1.65, a 3.5% decline from $1.71 in fiscal 2025. However, EPS is anticipated to grow 6.7% year-over-year to $1.76 in fiscal 2027. Shares of Bio-Techne have increased 35.3% over the past 52 weeks, exceeding both the S&P 500 Index's ($SPX) 18.4% gain and the State Street Health Care Select Sector SPDR ETF's (XLV) 21.4% return over the same period. Shares of Bio-Techne tumbled 16.4% on May 6 after the company reported weaker-than-expected Q3 2026 results, with revenue declining 2% year-over-year to $311.4 million and adjusted EPS falling to $0.53, as softer biotech spending continued to offset strong demand from large pharmaceutical customers. Investors were particularly concerned that organic revenue also declined 2%, driven by lower GMP fast-track orders, delayed large Commercial Supply shipments, and continued weak purchasing activity from emerging biotech clients despite an improving biotech funding environment. Analysts' consensus rating on TECH stock is cautious, with an overall "Hold" rating. Among 15 analysts covering the stock, two recommend a "Strong Buy,” 12 give a "Hold" rating, and one has a "Strong Sell.” As of writing, it is trading above the average analyst price target of $69.31. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bio-Techne (NASDAQ:TECH) and the best and worst performers in the research tools & consumables industry. The life sciences subsector specializing in research tools and consumables enables scientific discoveries across academia, biotechnology, and pharmaceuticals. These firms supply a wide range of essential laboratory products, ensuring a recurring revenue stream through repeat purchases and replenishment. Their business models benefit from strong customer loyalty, a diversified product portfolio, and exposure to both the research and clinical markets. However, challenges include high R&D investment to maintain technological leadership, pricing pressures from budget-conscious institutions, and vulnerability to fluctuations in research funding cycles. Looking ahead, this subsector stands to benefit from tailwinds such as growing demand for tools supporting emerging fields like synthetic biology and personalized medicine. There is also a rise in automation and AI-driven solutions in laboratories that could create new opportunities to sell tools and consumables. Nevertheless, headwinds exist. These companies tend to be at the mercy of supply chain disruptions and sensitivity to macroeconomic conditions that impact funding for research initiatives. The 10 research tools & consumables stocks we track reported a mixed Q1. As a group, revenues beat analysts’ consensus estimates by 1.3% while next quarter’s revenue guidance was 2% above. Luckily, research tools & consumables stocks have performed well with share prices up 21.8% on average since the latest earnings results. With a catalog of hundreds of thousands of specialized biological products used in laboratories worldwide, Bio-Techne (NASDAQ:TECH) develops and manufactures specialized reagents, instruments, and services that help researchers study biological processes and enable diagnostic testing and cell therapy development. Bio-Techne reported revenues of $311.4 million, down 1.5% year on year. This print fell short of analysts’ expectations by 1.6%. Overall, it was a softer quarter for the company with a miss of analysts’ organic revenue estimates and EPS in line with analysts’ estimates. "The Bio‑Techne team delivered solid execution amid a mixed end‑market environment," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. Bio-Techne delivered the slowest revenue growth in the group. Interestingly, the stock is up 26.1% since reporting and currently trades at $71.49. Read our full report on Bio-Techne here, it’s free. Founded in 1958 and pioneering innovations in laboratory analysis for over six decades, Waters (NYSE:WAT) develops and manufactures analytical instruments, software, and consumables for liquid chromatography, mass spectrometry, and thermal analysis used in scientific research and quality testing. Waters Corporation reported revenues of $1.27 billion, up 91.5% year on year, outperforming analysts’ expectations by 4.5%. The business had a very strong quarter with an impressive beat of analysts’ organic revenue estimates and revenue guidance for next quarter exceeding analysts’ expectations. Waters Corporation pulled off the biggest analyst estimate beat, highest guidance raise, and fastest revenue growth of the whole group. The market seems happy with the results as the stock is up 24% since reporting. It currently trades at $374.42. Is now the time to buy Waters Corporation? Access our full analysis of the earnings results here, it’s free. Formerly known as PerkinElmer until its rebranding in 2023, Revvity (NYSE:RVTY) provides health science technologies and services that support the complete workflow from discovery to development and diagnosis to cure. Revvity reported revenues of $686.9 million, up 9.3% year on year, falling short of analysts’ expectations by 2.6%. It was a softer quarter as it posted full-year revenue guidance missing analysts’ expectations significantly and a significant miss of analysts’ full-year EPS guidance estimates. Revvity delivered the weakest performance against analyst estimates and weakest full-year guidance update among its peers. Interestingly, the stock is up 28.7% since the results and currently trades at $111.35. Read our full analysis of Revvity’s results here. Originally spun off from Hewlett-Packard in 1999 as its measurement and analytical division, Agilent Technologies (NYSE:A) provides analytical instruments, software, services, and consumables for laboratory workflows in life sciences, diagnostics, and applied chemical markets. Agilent reported revenues of $1.84 billion, up 10% year on year. This print beat analysts’ expectations by 1.9%. Overall, it was a strong quarter as it also recorded an impressive beat of analysts’ organic revenue estimates and a narrow beat of analysts’ full-year EPS guidance estimates. Agilent achieved the highest full-year guidance raise but had the weakest guidance update in the group. The stock is up 16.3% since reporting and currently trades at $134.76. Read our full, actionable report on Agilent here, it’s free. With roots dating back to 1904 and embedded in virtually every stage of scientific research and production, Avantor (NYSE:AVTR) provides mission-critical products, materials, and services to customers in biopharma, healthcare, education, and advanced technology industries. Avantor reported revenues of $1.58 billion, flat year on year. This result surpassed analysts’ expectations by 2.7%. It was a very strong quarter as it also put up a solid beat of analysts’ organic revenue estimates and a beat of analysts’ EPS estimates. The stock is up 44.5% since reporting and currently trades at $11.36. Read our full, actionable report on Avantor here, it’s free. Over the past year, investors have been forced to repeatedly answer the same question: what is the market’s biggest risk? The answer has changed several times, and each shift has reshaped market leadership. Late in 2025 and early 2026, artificial intelligence became the market’s primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products. By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market’s dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals. Want to invest in winners with rock-solid fundamentals? Check out our Hidden Gem Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.

A month has gone by since the last earnings report for Techne (TECH). Shares have added about 4.5% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Techne due for a pullback? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent drivers for Bio-Techne Corp before we dive into how investors and analysts have reacted as of late. Bio-Technereported third-quarter fiscal 2026 adjusted earnings per share of 53 cents, which missed the Zacks Consensus Estimate by 2.8%. The bottom line was down 5.4% on a year-over-year basis. The quarter's adjustments eliminated the impact of certain one-time items, including amortization of Wilson Wolf intangible assets, and restructuring and restructuring-related costs, among others. GAAP earnings per share was 32 cents compared with 14 cents in the prior-year quarter. Bio-Techne registered net sales of $311.4 million, reflecting a decline of 1.5% year over year on a reported basis. The figure was down 2% on an organic basis. The top line missed the Zacks Consensus Estimate by 2.4%. Following the announcement, shares of Bio-Techne declined 1.2% in pre-market trading yesterday, reflecting investor reaction to the company’s quarterly sales and earnings decline. The company reports under two business segments — Protein Sciences, and Diagnostics and Spatial Biology (formerly Diagnostics and Genomics). Within Protein Sciences, Bio-Techne recorded revenues of $226.2 million, down 1% year over year (down 4% organically). In fiscal 2024, a business within this segment met the criteria as held-for-sale, excluded from its operating results. Within Diagnostics and Spatial Biology, sales decreased 4% year over year to $85.6 million (up 3% organically) in the fiscal third quarter. Within this, the Exosome Diagnostics business met the held-for-sale criteria, excluded from its operating results. Bio-Techne’s gross profit fell 2.9% to $208.3 million. The gross margin contracted 97 basis points (bps) to 66.9% on a 1.5% rise in the cost of sales. Selling, general and administrative expenses declined 27.7% to $109.3 million. Research and development expenses totaled $23.4 million, down 4.6% year over year. The company generated an operating profit of $75.5 million in the fiscal third quarter compared with the year-ago quarter’s figure of $38.7 million. The operating margin expanded 1200 bps to 24.2% during the quarter. Bio-Techne exited the fiscal third quarter of 2026 with cash and equivalents of $209.8 million compared with $172.9 million at the end of the fiscal second quarter. Long-term debt obligations totaled $200 million compared with $260 million in the previous quarter. Cumulative net cash provided by operating activities was $196.7 million compared with $189.3 million a year ago. In the past month, investors have witnessed a downward trend in estimates review. The consensus estimate has shifted -7.01% due to these changes. At this time, Techne has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy. Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Techne has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months. Techne is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Krystal Biotech, Inc. (KRYS), a stock from the same industry, has gained 3.7%. The company reported its results for the quarter ended March 2026 more than a month ago. Krystal Biotech reported revenues of $116.36 million in the last reported quarter, representing a year-over-year change of +32%. EPS of $1.83 for the same period compares with $1.20 a year ago. For the current quarter, Krystal Biotech is expected to post earnings of $1.81 per share, indicating a change of +40.3% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days. Krystal Biotech has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bio-Techne Corp (TECH) : Free Stock Analysis Report Krystal Biotech, Inc. (KRYS) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Bio-Techne’s first quarter was marked by a negative market reaction, with revenue coming in below Wall Street expectations. Management attributed the shortfall primarily to continued softness in emerging biotech demand and the impact of order timing from two cell therapy customers with FDA Fast Track Designation. CEO Kim Kelderman acknowledged that, despite stable performance from large pharmaceutical customers and improving trends in U.S. academia, the emerging biotech segment “was indeed our surprise,” as early-stage funding remained weak and order activity lagged expectations. Is now the time to buy TECH? Find out in our full research report (it’s free). Revenue: $311.4 million vs analyst estimates of $316.4 million (1.5% year-on-year decline, 1.6% miss) Adjusted EPS: $0.53 vs analyst estimates of $0.53 (in line) Adjusted EBITDA: $116.7 million vs analyst estimates of $115.4 million (37.5% margin, 1.1% beat) Operating Margin: 24.2%, up from 12.2% in the same quarter last year Organic Revenue fell 2% year on year (miss) Market Capitalization: $7.42 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Matthew Larew (William Blair) asked about intra-quarter biotech trends; CEO Kim Kelderman explained that, despite stronger funding, early-stage biotech funding was still down and customer order activity remained muted. Puneet Souda (Leerink Partners) questioned the potential for mid-single-digit growth next year; CFO James Hippel said he would be disappointed if that was not achieved, citing normalization trends and core business resilience. Patrick Donnelly (Citi) inquired about China’s outlook; Kelderman said the team expects continued momentum in China, citing direct market presence and strong customer ties as drivers. Justin Bowers (Deutsche Bank) sought clarity on early signs of a biotech recovery; Hippel pointed to rising interest and funnel growth within proteomic analysis and spatial biology as leading indicators, but cautioned that order conversion is not yet evident. Kyle Boucher (TD Cowen) asked about the sustainability of high growth in GMP reagent and spatial biology; Kelderman responded that deeper customer spend, expanding clinical programs, and market mix shifts are supporting these trends, though easy comps also help. In the next few quarters, the StockStory team will watch (1) whether emerging biotech order activity finally reflects the recent rebound in funding, (2) further traction and backlog expansion in the COMET and Ella platforms, and (3) continued stabilization in academic and international markets, particularly China. The normalization of order timing in cell therapy and OEM channels will also be key signposts for sustained revenue growth. Bio-Techne currently trades at $47.41, down from $56.68 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free for active Edge members). ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time. Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE. Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

Bio-Techne Corporation's (NASDAQ:TECH) earnings announcement last week didn't impress shareholders. However, our analysis suggests that the soft headline numbers are getting counterbalanced by some positive underlying factors. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. To properly understand Bio-Techne's profit results, we need to consider the US$157m expense attributed to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And, after all, that's exactly what the accounting terminology implies. Bio-Techne took a rather significant hit from unusual items in the year to March 2026. All else being equal, this would likely have the effect of making the statutory profit look worse than its underlying earnings power. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. As we mentioned previously, the Bio-Techne's profit was hampered by unusual items in the last year. Based on this observation, we consider it possible that Bio-Techne's statutory profit actually understates its earnings potential! On the other hand, its EPS actually shrunk in the last twelve months. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. While conducting our analysis, we found that Bio-Techne has 1 warning sign and it would be unwise to ignore it. Today we've zoomed in on a single data point to better understand the nature of Bio-Techne's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.